{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:43:52Z","timestamp":1790768632802,"version":"4.1.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>John Martin\u2019s untimely death in March 2021 was a huge loss for us personally, Gilead Sciences, the company he built over 30\u00a0years and the scientific community concerned with antiviral therapies. We wish to honor John\u2019s legacy by retelling the discovery and history of Tamiflu and his contributions to it. Without his vision, persistence, and keen eye for opportunities, Tamiflu would not exist and Gilead\u2019s path would not have been the same. His strategic thinking around the first oral flu drug is still quite relevant today, when we are still in the SARS-CoV-2 pandemic. John explained it simply in an interview with the Science History Institute in May 2020: \u201c\u2026 most of my colleagues, we travel with Tamiflu when we go internationally, because it works for treatment and prevention, and hopefully, there will be a solution like that, eventually, for the Covid virus in addition to vaccines. Most people will get a flu vaccine every year, but there is still disease, we need a pill for treatment and prevention.\u201d<\/jats:p>","DOI":"10.1177\/13596535211067598","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T02:57:39Z","timestamp":1651460259000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Discovery and development of oseltamivir at Gilead Sciences"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-0150","authenticated-orcid":false,"given":"Uli","family":"Schmitz","sequence":"first","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swami","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,1]]},"reference":[{"key":"bibr1-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-92165-3"},{"key":"bibr2-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511586576"},{"key":"bibr3-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610941104"},{"key":"bibr4-13596535211067598","unstructured":"CDC. 1918 Pandemic (H1N1 Virus). https:\/\/www.cdc.gov\/flu\/pandemic-resources\/1918-pandemic-h1n1.html"},{"key":"bibr5-13596535211067598","volume-title":"H1N1 Pandemic (H1N1pdm09 Virus)","author":"CDC","year":"2009"},{"key":"bibr6-13596535211067598","volume-title":"Roche Annual Report","author":"Roche","year":"2010"},{"key":"bibr7-13596535211067598","volume-title":"69, Dies; Led Drugmaker in Breakthroughs","author":"Robert S","year":"2021"},{"key":"bibr8-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1021\/jm00359a023"},{"key":"bibr9-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1021\/bi00059a003"},{"key":"bibr10-13596535211067598","doi-asserted-by":"publisher","DOI":"10.11116\/9789461662453"},{"key":"bibr11-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1038\/303041a0"},{"key":"bibr12-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1038\/303035a0"},{"key":"bibr13-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(74)90080-4"},{"key":"bibr14-13596535211067598","volume-title":"Biota. Anti-viral Compounds that Bind the Active Site of Influenza Neuraminidase and Display in Vivo Activity against Orthomyxovirus and Paramyxovirus","year":"1992"},{"key":"bibr15-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05026.x"},{"key":"bibr16-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1126\/science.2781276"},{"key":"bibr17-13596535211067598","volume-title":"Biota. Derivatives and Analogues of 2-Deoxy-2,3-Didehydro-N-Acetyl Neuraminic Acid and Their Use as Antiviral Agents","year":"1991"},{"key":"bibr18-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1016\/0960-894X(95)00390-F"},{"key":"bibr19-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1021\/ja963036t"},{"key":"bibr20-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1021\/jm980162u"},{"key":"bibr21-13596535211067598","doi-asserted-by":"publisher","DOI":"10.2174\/0929867003374886"},{"key":"bibr22-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-894x(00)00214-6"},{"key":"bibr23-13596535211067598","volume-title":"Novel selective inhibitors of viral or bacterial neuraminidases","author":"Bischofberger N","year":"1996"},{"key":"bibr24-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.647"},{"key":"bibr25-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.640"},{"key":"bibr26-13596535211067598","volume-title":"Gilead Sciences","author":"Gilead Sciences H-LR","year":"1996"},{"key":"bibr27-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.13.1240"},{"key":"bibr28-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1177\/135965350000500305"},{"key":"bibr29-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg007"},{"key":"bibr30-13596535211067598","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464180-00003"},{"key":"bibr31-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200102000-00002"},{"key":"bibr32-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.8.1016"},{"key":"bibr33-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02288-1"},{"key":"bibr34-13596535211067598","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161020-00011"},{"key":"bibr35-13596535211067598","volume-title":"Tamiflu\u2122 Granted FDA Approval for Treatment of Flu in Children","author":"Gilead Sciences","year":"2001"},{"key":"bibr36-13596535211067598","volume-title":"Gilead Sciences Announces Termination of its U.S","author":"Gilead Sciences","year":"1999"},{"key":"bibr37-13596535211067598","volume-title":"US FDA Approves Gilead Sciences\u2019 Anti-HIV Drug Viread\u2122","author":"Gilead Sciences","year":"2001"},{"key":"bibr38-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f547"},{"key":"bibr39-13596535211067598","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.01.014"},{"key":"bibr40-13596535211067598","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00039"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535211067598","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535211067598","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535211067598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:04Z","timestamp":1777380784000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535211067598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1177\/13596535211067598"],"URL":"https:\/\/doi.org\/10.1177\/13596535211067598","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"article-number":"13596535211067598"}}